University of Hyderabad (UoH) has signed an MoU with Natco Pharma for carrying out advance research in the areas of discovery of novel drugs and their delivery systems among others.
According to a release issued by the university today, the research includes nano formulations of new chemical entities and novel biotechnological processes for specific products with potential commercial importance.
Both the parties will promote cooperation in academic exchange, research and development collaborations, training and research in the areas of biotechnology, pharmacology, toxicology, pharmaceutical technology and organisation of national and international conferences, exhibition and similar events in areas of mutual interest, it said.
School of Life Sciences of UoH has been undertaking collaborative research in the areas of drug discovery for the past several years with Natco. The research has resulted in developing one of the molecules to Phase-II clinical trials for the treatment of chronic myeloid leukaemia, it added.
The MoU, signed for a period of five years, will foster the academy-industry interactions by utilisation of expertise of the faculty and infrastructural facilities for promoting anti-cancer drug discovery research and development at Natco, it said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
